David Neal Fass

US Patent:

20090215070, Aug 27, 2009

Filed:

Jul 13, 2006

Appl. No.:

11/988518

Inventors:

Kenneth G. Mann - Grand Isle VT, US
David N. Fass - Rochester MN, US

Assignee:

The University of Vermont and State Agriculture College - Burlington VT

International Classification:

G01N 33/53
C07K 16/36

US Classification:

435 71, 5303893

Abstract:

Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.

US Patent:

20130115621, May 9, 2013

Filed:

Jul 18, 2012

Appl. No.:

13/552246

Inventors:

Kenneth G. Mann - Grand Isle VT, US
David N. Fass - Rochester MN, US

Assignee:

The University of Vermont and State Agriculture College - Burlington VT

International Classification:

G01N 33/86

US Classification:

435 75, 5303893

Abstract:

Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.